ArticleScientific reports2026
Targeting NF-kappa B/proinflammatory cytokines/ TGF-β/ TIMP-1 pathway by crocin enhances recovery from hepatic fibrosis in rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structural and Functional Characteristics of the Liver After Fractionated Local Electron Irradiation and Against the Background of Ascorbic Acid Administration.Journal of personalized medicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver fibrosis is a dynamic and potentially reversible process until irreversible structural changes occur. This study evaluated the curative effect of crocin on carbon tetrachloride (CCl₄)-induced hepatic fibrosis in rats and explored the underlying mechanisms.
methodsThirty male rats were allocated into three groups: a control group treated subcutaneously (SC) with corn oil for 8 weeks followed by intraperitoneal (IP) saline for 2 weeks; a spontaneous recovery group (CCl₄-SC for 8 weeks followed by saline IP for 2 weeks); and a crocin recovery group (CCl₄-SC for 8 weeks followed by crocin 100 mg/kg/day IP for 2 weeks). Liver function tests, fibrosis biomarkers, collagen deposition, inflammatory mediators, oxidative stress indices, and the gene expression of collagen I and α-SMA were assessed using ELISA, spectrophotometry, or qRT-PCR.
resultsCrocin significantly improved liver function and reduced fibrosis markers (hyaluronic acid, laminin, PCIII, hydroxyproline, TGF-β, TIMP-1). Furthermore, it downregulated collagen I and α-SMA expression and suppressed NF-κB mediated inflammatory cytokines (TNF-α, IL-1β, NO). It also enhanced antioxidant defenses (GSH, SOD, catalase, GSH-Px) compared with the spontaneous recovery group.
conclusionCrocin exerts a promising curative effect against CCl₄-induced hepatic fibrosis in rats by suppressing NF-κB driven inflammation and profibrogenic mediators, thereby limiting collagen deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.